Expression of microRNA-133a and microRNA-208b in Acute Myocardial Infarction

Sponsor
Islamia University of Bahawalpur (Other)
Overall Status
Completed
CT.gov ID
NCT05692752
Collaborator
German University in Cairo (Other)
10
1
17
17.9

Study Details

Study Description

Brief Summary

Cardiac-enriched micro-RNAs (miRNAs), micro RNA 208b and 133a(MiR-208b, MiR-133a)) corresponds to the health and disorders of the cardiovascular system. An intron of the cardiac myosin heavy chain gene MYH7 encodes miR-208b. It is found on chromosome 14 in humans. Identify new diagnostic biomarkers based on miRNAs, researchers examine the expression of miR-133a and 208b at various time points (04 hours, 08 hours, 12 hours, 24 hours, 48 hours) following the development of the infarct and compared it to the traditional myocardial infarction biomarkers cardiac troponine (cTnl) and Creatine kinase-MB (CK-MB).

Condition or Disease Intervention/Treatment Phase
  • Other: No intervention

Detailed Description

The 98% of human genes are non-coding RNA, which is further divided into long non-coding RNA (lncRNA, > 200 bp) and short non-coding RNA (200 bp, including microRNA (miRNA) and circular RNA). More than 2000 human miRNAs have been discovered, and it seems that they regulate around 60% of human genes.Through a number of pathways, miRNAs control the development, re-modelling, and regeneration of the heart as well as endothelial function, vasculo-genesis, and neoangiogenesis. 30% of the genes in the human genome are regulated by about 1000 miRNAs. Endogenous miRNAs are 19-22 nucleotide single-stranded RNA molecules that frequently target the 3' untranslated regions (3'-UTR) of mRNAs to regulate gene expression at the post-transcriptional level in physiological processes, disease development, and conditions like cancer, autoimmune and inflammatory diseases, neuro-degenerative diseases, and cardiovascular diseases. Cardiac-enriched miRNAs, MiR-208 in health and disorders of the cardiovascular system are investigated.

Identify new diagnostic biomarkers based on miRNAs, researchers examine the expression of miR-133a and 208b at various time points (04 hours, 08 hours, 12 hours, 24 hours, 48 hours) following the development of the infarct and compared it to the traditional myocardial infarction biomarkers cTnl and CK-MB.

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
10 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Expression of microRNA-133a and microRNA-208b in Acute Myocardial Infarction Egyptian Patients
Actual Study Start Date :
Dec 28, 2022
Actual Primary Completion Date :
Jan 10, 2023
Actual Study Completion Date :
Jan 14, 2023

Arms and Interventions

Arm Intervention/Treatment
Test Group

The study group included 10 patients, men and women between age of 35-60 year chest pain lasting for at least 30 minutes, electrocardiogram (ECG) finding that display ST-segment elevation (STEMI)

Other: No intervention
Expression of miR-133a &208b at 4, 8, 12, 24 and 48 hours from the first appearance of myocardial infarction (MI) symptoms
Other Names:
  • Expression of miR-133a & 208b
  • Control Group

    The study group included 10 patients, men and women between age of 35-60 year having no complaint of health issue,

    Other: No intervention
    Expression of miR-133a &208b at 4, 8, 12, 24 and 48 hours from the first appearance of myocardial infarction (MI) symptoms
    Other Names:
  • Expression of miR-133a & 208b
  • Outcome Measures

    Primary Outcome Measures

    1. Expression of miR-133a [04 hours from the onset of the infarct]

      Expression during episodes of myocardial infarction

    2. Expression of miR-133a [08 hours from the onset of the infarct]

      Expression during episodes of myocardial infarction

    3. Expression of miR-133a [12 hours from the onset of the infarct]

      Expression during episodes of myocardial infarction

    4. Expression of miR-133a [24 hours from the onset of the infarct]

      Expression during episodes of myocardial infarction

    5. Expression of miR-133a [48 hours from the onset of the infarct]

      Expression during episodes of myocardial infarction

    6. Expression of miR-208b [04 hours from the onset of the infarct]

      Expression during episodes of myocardial infarction

    7. Expression of miR-208b [08 hours from the onset of the infarct]

      Expression during episodes of myocardial infarction

    8. Expression of miR-208b [12 hours from the onset of the infarct]

      Expression during episodes of myocardial infarction

    9. Expression of miR-208b [24 hours from the onset of the infarct]

      Expression during episodes of myocardial infarction

    10. Expression of miR-208b [48 hours from the onset of the infarct]

      Expression during episodes of myocardial infarction

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    35 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    1. Patients diagnosed with ST-Elevated Myocardial Infarction will be identified at the Coronary Care Unit at Ain-shams University hospital

    2. Acute episode of Myocardial Infarction

    3. With No history of previous Myocardial Infarction Treatment

    Exclusion Criteria:
    1. Patients not diagnosed with ST-Elevated Myocardial Infarction and healthy at the Coronary Care Unit at Ain-shams 2. University hospital

    2. Previously Known patients of Myocardial infacrtion

    3. Previous medication

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Biochemistry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Main Entrance Al Tagamoa Al Khames Cairo Egypt 11835

    Sponsors and Collaborators

    • Islamia University of Bahawalpur
    • German University in Cairo

    Investigators

    • Principal Investigator: Sally I Hassanien, Ph.D, Biochemistry Department German University in Cairo, 11835, Cairo, Egypt
    • Principal Investigator: Hafiz A Sattar, M.Phil, University College of Conventional Medicine, The Islamia University of Bahawalpur, Punjab, Pakistan

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hafiz Abdul Sattar Hashmi, Lecturer, Islamia University of Bahawalpur
    ClinicalTrials.gov Identifier:
    NCT05692752
    Other Study ID Numbers:
    • UCCM/2022/EGT/01
    First Posted:
    Jan 20, 2023
    Last Update Posted:
    Jan 20, 2023
    Last Verified:
    Jan 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 20, 2023